紫杉醇涂层器械治疗外周动脉疾病的结局
单中心回顾性研究纳入2013至2016年接受下肢动脉腔内治疗的366例患者,其中138例使用紫杉醇涂层器械。平均随访3.1±1.8年,涂层器械组与非涂层器械组在全因死亡率(16% vs 20%;
要点
- 主要截肢率、再干预率及一期通畅率两组间无显著差异。
核心结论
- 紫杉醇涂层器械治疗外周动脉疾病是安全的,未增加长期死亡风险。
- 仍需持续监测紫杉醇涂层器械的使用以确保安全性。
研究设计与样本
- 单中心回顾性研究,纳入2013至2016年因外周动脉疾病行腔内治疗的366例患者。
- 138例(38%)使用紫杉醇涂层器械,228例(62%)使用非药物涂层器械。
- 对接受多次干预的患者计算紫杉醇累积剂量,并比较两组死亡原因。
主要发现
- 一期通畅率、再干预率及平均再干预次数两组间均无差异。
- Kaplan-Meier生存曲线及Cox回归分析显示涂层器械使用与死亡风险增加无关。
临床怎么用
- 在充分知情的前提下,可考虑使用紫杉醇涂层器械治疗股腘动脉外周动脉疾病。
- 对接受多次紫杉醇涂层器械干预的患者,可记录累积剂量但无需因剂量高而改变治疗决策。
- 应继续对使用紫杉醇涂层器械的患者进行长期随访监测。
局限性
- 本研究为单中心回顾性研究,样本量有限,可能存在选择偏倚。
- 平均随访时间3.1±1.8年,不足以评估更长期的死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The treatment of femoropopliteal peripheral artery disease (PAD) using paclitaxel-coated devices (PCDs) has been shown to improve patency in several randomized trials. However, a recent meta-analysis of trial data suggested an increased risk of mortality with PCD usage. Although subsequent studies have found no association with mortality, the subject has remained controversial. Thus, the aim of the present study was to further investigate the outcomes and causes of mortality for patients treated with PCDs. METHODS: Patients who had undergone endovascular interventions for PAD from 2013 to 2016 at a single institution were reviewed. The patients were stratified by the use of PCDs, which included drug-coated balloons and drug-eluting stents. The cumulative dose of paclitaxel was calculated for the patients who had received multiple interventions. The causes of mortality were identified and compared between the two groups. RESULTS: Of the 366 included patients, 138 (38%) had received a PCD and 228 (62%) had received a non-drug-coated (NDC) device. Patients treated with PCDs were less likely to have undergone open surgery compared with patients treated with NDC devices. No differences were found in the indications or 30-day outcomes between the two groups. After a mean follow-up of 3.1 ± 1.8 years, no differences were found in the primary patency, reintervention rate, mean number of reinterventions, major amputation (5% vs 4%; P = .465), or mortality (16% vs 20%; P = .363) between the PCD and NDC groups. Also, no overall difference was found in the cause of mortality with and without PCD use or in the Kaplan-Meier survival curves. Furthermore, PCD use was not associated with an increased risk of mortality in Cox regression analysis. The cumulative dose of paclitaxel in patients treated with PCDs ranged from 383 to 49,259 μg (median, 7561 μg). A comparison of the patients treated with a cumulative dose of paclitaxel in the upper 50th percentile compared with the lower 50th percentile showed no significant differences in mortality (13% vs 19%; P = .333). CONCLUSIONS: PCD use was shown to be safe and not associated with an increased risk of long-term mortality in the present study. Continued monitoring of PCD use is warranted to ensure the safety of this technology.
引用
- Kim TI, Kiwan G, Mohamedali A, et al. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. J Vasc Surg. 2020. PMID: 33038480. doi:10.1016/j.jvs.2020.08.146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。